儿童和青少年多发性硬化症的诊断与治疗：现状与未来疗法
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.
作者信息
Yeh E Ann
机构信息
Department of Neurology, Pediatric MS Center of the JNI, SUNY Buffalo, Buffalo, NY, USA.
出版信息
Adolesc Health Med Ther. 2010 Jul 30;1:61-71. doi: 10.2147/AHMT.S8130. eCollection 2010.
Abstract
Pediatric-onset multiple sclerosis (MS) comprises approximately 3%-5% of cases of MS in North America. Recent years have seen significant advances in the diagnosis and treatment of this condition, including the introduction of proposed diagnostic criteria for pediatric demyelinating disorders, and a growing body of knowledge regarding treatment options. This article reviews current approaches to the diagnosis and management of pediatric MS.
摘要
儿童期多发性硬化症（MS）约占北美MS病例的3% - 5%。近年来，这种疾病的诊断和治疗取得了重大进展，包括提出了儿童脱髓鞘疾病的诊断标准，以及关于治疗选择的知识不断增加。本文综述了儿童MS诊断和管理的当前方法。
相似文献
1
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.儿童和青少年多发性硬化症的诊断与治疗：现状与未来疗法
Adolesc Health Med Ther. 2010 Jul 30;1:61-71. doi: 10.2147/AHMT.S8130. eCollection 2010.
2
What is new in the treatment of multiple sclerosis?多发性硬化症治疗方面有哪些新进展？
Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002.
3
Natalizumab in pediatric multiple sclerosis patients.那他珠单抗在儿科多发性硬化症患者中的应用。
Ther Adv Neurol Disord. 2010 Sep;3(5):293-9. doi: 10.1177/1756285610381526.
4
Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.巴西患儿多发性硬化症：临床特征、治疗反应及与小儿视神经脊髓炎谱系疾病的比较。
Mult Scler Relat Disord. 2018 Oct;25:138-142. doi: 10.1016/j.msard.2018.07.036. Epub 2018 Jul 20.
5
Pediatric multiple sclerosis.小儿多发性硬化症
Handb Clin Neurol. 2013;112:1263-74. doi: 10.1016/B978-0-444-52910-7.00049-0.
6
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.儿童多发性硬化的一线疾病修正治疗：全面概述。
Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000.
7
Saudi consensus recommendations on the management of multiple sclerosis: MS management in children and adolescents.沙特关于多发性硬化症管理的共识建议：儿童和青少年的多发性硬化症管理
Mult Scler Relat Disord. 2022 Oct;66:104061. doi: 10.1016/j.msard.2022.104061. Epub 2022 Jul 17.
8
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.多发性硬化症：现有和新兴的疾病修正治疗方法和治疗策略。
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
9
Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report.误诊为多发性硬化症患者在接受干扰素-β-1a 和那他珠单抗治疗期间出现 Susac 综合征：病例报告。
BMC Ophthalmol. 2021 Sep 30;21(1):352. doi: 10.1186/s12886-021-02101-3.
10
[Background of the new definitions for pediatric multiple sclerosis].[小儿多发性硬化新定义的背景]
Nihon Rinsho. 2010 Jan;68(1):57-61.
引用本文的文献
1
Diagnosis and Management of Multiple Sclerosis in Children.儿童多发性硬化症的诊断与管理
Iran J Child Neurol. 2016 Summer;10(3):13-23.
本文引用的文献
1
Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis.抗髓鞘抗体调节儿童多发性硬化症的临床表现。
J Neuroimmunol. 2010 Jun;223(1-2):92-9. doi: 10.1016/j.jneuroim.2010.02.019. Epub 2010 Apr 8.
2
A comparison of MRI criteria for diagnosing pediatric ADEM and MS.儿童 ADEM 和 MS 的 MRI 诊断标准比较。
Neurology. 2010 May 4;74(18):1412-5. doi: 10.1212/WNL.0b013e3181dc138b. Epub 2010 Mar 24.
3
Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis.血管周围脱髓鞘：与临床定义的急性播散性脑脊髓炎的关联，并与经病理证实的多发性硬化症进行比较。
Brain. 2010 Feb;133(Pt 2):333-48. doi: 10.1093/brain/awp321. Epub 2010 Feb 3.
4
Younger children with MS have a distinct CSF inflammatory profile at disease onset.发病时，年幼的多发性硬化症患儿的脑脊液具有明显的炎症特征。
Neurology. 2010 Feb 2;74(5):399-405. doi: 10.1212/WNL.0b013e3181ce5db0.
5
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.一项口服克拉屈滨治疗复发型多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.
6
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
7
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
8
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.口服芬戈莫德（FTY720）在多发性硬化症中的作用机制。
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101. doi: 10.1097/WNF.0b013e3181cbf825.
9
Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis.儿童发病多发性硬化症患儿和成人的磁共振成像特征。
Brain. 2009 Dec;132(Pt 12):3392-400. doi: 10.1093/brain/awp278.
10
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.需要对多发性硬化症人群中米托蒽醌治疗后继发白血病的风险进行修订。
Mult Scler. 2009 Nov;15(11):1303-10. doi: 10.1177/1352458509107015. Epub 2009 Oct 13.
Zotero 插件